EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant recipients: a systematic review and meta-analysis

Kasama Manothummetha, Thanuthong Mongkolkaew, Punyot Tovichayathamrong, Rabhas Boonyawairote, Tanaporn Meejun, Karan Srisurapanont, Kasidis Phongkhun, Anawin Sanguankeo, Pattama Torvorapanit, Chatphatai Moonla, Rongpong Plongla, Olivia S Kates und 3 weitere

Clinical Microbiology and Infection · 2023

DOI: 10.1016/j.cmi.2023.04.021 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Microbiology and Infection, 2023. Verfasst von Kasama Manothummetha und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hematologic Neoplasms, Respiratory Tract Infections, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: School of Medicine, Johns Hopkins University, Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ribavirin use for respiratory syncytial virus (RSV) infection in patients with haematologic malignancies (HM) and haematopoietic stem cell transplant (HSCT) recipients remains controversial. OBJECTIVES: To summarize the current evidence of ribavirin treatment in association with mortality and progression to lower respiratory tract infection (LRTI) among patients with HM/HSCT with RSV infection. DATA SOURCES: MEDLINE, Embase, and the Institute for Scientific Information Web of Science. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials and observational studies investigating the effects of ribavirin, compared with treatment without ribavirin, for RSV infection. PARTICIPANTS: Patients with HM/HSCT. INTERVENTIONS: Ribavirin versus no ribavirin. ASSESSMENT OF RISK OF BIAS: The risk of bias in non-randomized studies of exposure (ROBIN-E). METHODS OF DATA SYNTHESIS: The random-effects model was used to calculate the pooled OR (pOR) with 95% CI for the pooled effect estimates of ribavirin benefits. Grading of recommendation assessment, development, and evaluation was used to evaluate the certainty of evidence. RESULTS: One randomized controlled trial and 14 observational studies were included, representing 1125 patients with HM/HSCT. Ribavirin use was not associated with lower all-cause or RSV-associated mortality with pORs [95% CI] of 0.81 [0.40, 1.66], I2 = 55% (low certainty of evidence) and 0.48 [0.11, 2.15], I2 = 64% (very low certainty of evidence), respectively. In subgroup analyses, ribavirin use was associated with lower mortality in patients with HM/HSCT with LRTI with pOR [95% CI] of 0.19 [0.07, 0.51], I2 = 0% (moderate certainty of evidence). In subgroup analyses among studies providing adjusted OR, ribavirin use was associated with lower all-cause mortality with pOR of 0.41 [0.23, 0.74], I2 = 0% (moderate certainty of evidence). In addition, aerosolized ribavirin was associated with lower progression to LRTI with pOR [95% CI] of 0.27 [0.09, 0.80], I2 = 71% (low certainty of evidence). CONCLUSIONS: Ribavirin may be a reasonable option to treat RSV in patients with HM/HSCT in the absence of other effective antiviral agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsHematologic NeoplasmsRespiratory Tract InfectionsHematopoietic Stem Cell TransplantationHumansRibavirinAntiviral Agents

Stichwörter der Autor:innen

Haematologic malignancyHaematopoietic stem cell transplantRSVRespiratory syncytial virusRibavirin

Substanzen

RibavirinAntiviral Agents

Autor:innen und Institutionen

  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Department of Biotechnology, Graduate School of Engineering, Osaka University, Osaka, Japan.
  • Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Förderung

  • School of Medicine, Johns Hopkins University
  • Chulalongkorn University

Zitieren

APA

Manothummetha, K., Mongkolkaew, T., Tovichayathamrong, P., Boonyawairote, R., Meejun, T., Srisurapanont, K., Phongkhun, K., Sanguankeo, A., Torvorapanit, P., Moonla, C., Plongla, R., Kates, O. S., Avery, R. K., Nematollahi, S., & Permpalung, N. (2023). Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2023.04.021

Vancouver

Manothummetha K, Mongkolkaew T, Tovichayathamrong P, Boonyawairote R, Meejun T, Srisurapanont K, et al. Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2023. doi:10.1016/j.cmi.2023.04.021

BibTeX
@article{Manothummetha2023,
  author = {Manothummetha, Kasama and Mongkolkaew, Thanuthong and Tovichayathamrong, Punyot and Boonyawairote, Rabhas and Meejun, Tanaporn and Srisurapanont, Karan and Phongkhun, Kasidis and Sanguankeo, Anawin and Torvorapanit, Pattama and Moonla, Chatphatai and Plongla, Rongpong and Kates, Olivia S and Avery, Robin K and Nematollahi, Saman and Permpalung, Nitipong},
  title = {Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant recipients: a systematic review and meta-analysis},
  journal = {Clinical Microbiology and Infection},
  year = {2023},
  doi = {10.1016/j.cmi.2023.04.021}
}
Kostenlos starten →